Epizyme Appoints CEO

Epizyme, Inc., a clinical stage biopharmaceutical R&D company creating epigenetic therapeutics for cancer patients, has named Robert Bazemore president and CEO, effective Sept. 10, 2015. Bazemore will also join the Epizyme board of directors. He succeeds Dr Robert Gould who has served on the Epizyme board of directors since 2008 and as CEO for the past five-and-a-half years. Following the transition, Gould will continue to serve on the board and as a consultant to the company.